Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic liver disease (SLD).

GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from Boston Pharmaceuticals in a $2bn deal. The transaction includes an ...

Efimosfermin is being developed to treat and prevent the progression of steatotic liver disease (SLD), a build-up of fat in liver cells. SLD is a broad disease term used to encompass various ...

Efimosfermin is a novel, once-monthly fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH ...

Investigational efimosfermin alfa was safe and well tolerated among patients with phenotypic metabolic dysfunction-associated steatohepatitis (MASH), a randomized phase IIa trial showed. Among 65 ...

GSK indicated that the addition of efimosfermin expands its pipeline for fibro-inflammatory diseases across liver, lung, and kidney. The company is also developing GSK’990, a siRNA therapeutic ...

Given efimosfermin’s direct antifibrotic mechanism of action and GSK’s data-driven insights from work in human genetics and disease phenotyping, it has potential to address more advanced ...

Efimosfermin is a novel, once-monthly fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), ...